Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference

GlobeNewswire

2024-09-24

BURLINGTON, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D)), today announced that Harith Rajagopalan, M.D., Ph.D., Co-founder and Chief Executive Officer of Fractyl Health, will participate in a fireside chat at Chardan’s 8^th Annual Genetic Medicines Conference on Tuesday, October 1, 2024, at 9:00 a.m. EDT.

To register in advance for the presentation webcast, sign up here.

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.fractyl.com/.

About Fractyl Health

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com.

Contacts

Corporate Contact
Lisa Davidson, Chief Financial Officer
ir@fractyl.com, 781.902.8800

Media Contact
Jessica Cotrone, Corporate Communications
jcotrone@fractyl.com, 978.760.5622

Investor Contact
Stephen Jasper, Gilmartin Group
stephen@gilmartinir.com, 619.949.3681

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2469469245"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2469469245\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2469469245?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-24 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2469469245","market":"hk","top_or_hot":-1,"title":"Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference","media":"GlobeNewswire","content":"<html><body><p>BURLINGTON, Mass., Sept.  24, 2024  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/GUTS\">Fractyl Health</a>, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D)), today announced that Harith Rajagopalan, M.D., Ph.D., Co-founder and Chief Executive Officer of Fractyl Health, will participate in a fireside chat at Chardan’s 8<sup>th</sup> Annual Genetic Medicines Conference on Tuesday, October 1, 2024, at 9:00 a.m. EDT.<br/></p> <p>To register in advance for the presentation webcast, sign up <strong>here.</strong></p> <p>A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at <strong>https://ir.fractyl.com/</strong>.</p> <p><strong>About Fractyl Health</strong></p> <p>Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit <strong>www.fractyl.com</strong>.</p> <p><strong>Contacts </strong></p> <p><strong>Corporate Contact </strong><br/>Lisa Davidson, Chief Financial Officer <br/><strong>ir@fractyl.com</strong>, 781.902.8800</p> <p><strong>Media Contact </strong><br/>Jessica Cotrone, Corporate Communications<br/><strong>jcotrone@fractyl.com</strong>, 978.760.5622</p> <p><strong>Investor Contact</strong><br/>Stephen Jasper, Gilmartin Group<br/><strong>stephen@gilmartinir.com</strong>, 619.949.3681</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MDJiNDY3NmMtMGM5Yi00NTM3LWE3Y2UtMzQ3MDY2OTY4OTA3LTExOTM1ODM=/tiny/Fractyl-Health-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2024-09-24 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>BURLINGTON, Mass., Sept.  24, 2024  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/GUTS\">Fractyl Health</a>, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D)), today announced that Harith Rajagopalan, M.D., Ph.D., Co-founder and Chief Executive Officer of Fractyl Health, will participate in a fireside chat at Chardan’s 8<sup>th</sup> Annual Genetic Medicines Conference on Tuesday, October 1, 2024, at 9:00 a.m. EDT.<br/></p> <p>To register in advance for the presentation webcast, sign up <strong>here.</strong></p> <p>A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at <strong>https://ir.fractyl.com/</strong>.</p> <p><strong>About Fractyl Health</strong></p> <p>Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit <strong>www.fractyl.com</strong>.</p> <p><strong>Contacts </strong></p> <p><strong>Corporate Contact </strong><br/>Lisa Davidson, Chief Financial Officer <br/><strong>ir@fractyl.com</strong>, 781.902.8800</p> <p><strong>Media Contact </strong><br/>Jessica Cotrone, Corporate Communications<br/><strong>jcotrone@fractyl.com</strong>, 978.760.5622</p> <p><strong>Investor Contact</strong><br/>Stephen Jasper, Gilmartin Group<br/><strong>stephen@gilmartinir.com</strong>, 619.949.3681</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MDJiNDY3NmMtMGM5Yi00NTM3LWE3Y2UtMzQ3MDY2OTY4OTA3LTExOTM1ODM=/tiny/Fractyl-Health-Inc-.png\"/></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"醫療保健設備","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2024/09/24/2952022/0/en/Fractyl-Health-to-Present-at-Chardan-s-8th-Annual-Genetic-Medicines-Conference.html","article_id":"2469469245","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2469469245","pubTimestamp":1727175600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"BURLINGTON, Mass., Sept.  24, 2024  (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root cause","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","BK4121":"生命科学工具和服务","MDCO":"麦迪逊医药","GUTS":"Fractyl Health"},"translate_title":"Fractyl Health将出席Chardan第八届基因医学年会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GENE":1,"GUTS":1,"MDCO":1},"content_text":"BURLINGTON, Mass., Sept.  24, 2024  (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D)), today announced that Harith Rajagopalan, M.D., Ph.D., Co-founder and Chief Executive Officer of Fractyl Health, will participate in a fireside chat at Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024, at 9:00 a.m. EDT. To register in advance for the presentation webcast, sign up here. A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.fractyl.com/. About Fractyl Health Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com. Contacts  Corporate Contact Lisa Davidson, Chief Financial Officer ir@fractyl.com, 781.902.8800 Media Contact Jessica Cotrone, Corporate Communicationsjcotrone@fractyl.com, 978.760.5622 Investor ContactStephen Jasper, Gilmartin Groupstephen@gilmartinir.com, 619.949.3681","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}